Skip to main content
. 2020 Jul 22;7(8):1327–1339. doi: 10.1002/acn3.51121

Figure 6.

Figure 6

Changes in MG‐ADL LS mean domain scores from open‐label baseline to week 130 for (A) ocular, (B) bulbar, (C) respiratory, and (D) limb domains. *P ≤ 0.05, † P ≤ 0.01, ‡ P ≤ 0.001 compared with open‐label baseline, repeated‐measures analysis. Patient numbers were not the same for each assessment. Stable scores in the eculizumab/eculizumab group are evidence of maintained improvement achieved during eculizumab treatment in REGAIN in these patients. Data are from patients with abnormal domain scores at REGAIN baseline only. BL = baseline; CI = confidence interval; LS = least‐squares; MG‐ADL = myasthenia gravis activities of daily living profile.